Category: Serotonin

Evaluation of Post–COVID-19 Cognitive Dysfunction: Recommendations for Researchers

Posted on | Posted on John Murphy | Leave a Comment on Evaluation of Post–COVID-19 Cognitive Dysfunction: Recommendations for Researchers

Jaqueline H. Becker, PhD1; Tracy D. Vannorsdall, PhD2; Sara L. Weisenbach, PhD3, JAMA Psychiatry. 2023;80(11):1085-1086. doi:10.1001/jamapsychiatry.2023.2820 SARS-CoV-2 infection is associated with increased rates of postillness cognitive dysfunction, colloquially referred to as “brain fog,”1 that may portend significant consequences for patient functioning and quality of life. Post–COVID-19 cognitive dysfunction is 1 of approximately 200 symptoms of post–COVID-19 condition (PCC), defined by the World Health Organization as […]

Long COVID Linked With Viral Persistence, Serotonin Decline

Posted on | Posted on John Murphy | Leave a Comment on Long COVID Linked With Viral Persistence, Serotonin Decline

Emily Harris, JAMA. Published online November 1, 2023. doi:10.1001/jama.2023.21170 A study linking viral infection with reduced levels of serotonin, a neurotransmitter involved in learning, memory, and mood, has proposed a new potential mechanism underlying post–COVID-19 condition. Also known as long COVID, the condition involves symptoms such as fatigue, memory loss, and cognitive impairment. Using results from human participants, […]

Serotonin reduction in post-acute sequelae of viral infection

Posted on | Posted on John Murphy | Leave a Comment on Serotonin reduction in post-acute sequelae of viral infection

Andrea C. Wong, Ashwarya S. Devason, Iboro C. Umana, Sara Cherry, Christoph A. Thaiss, Maayan Levy 2Open Access Published:October 16, 2023DOI:https://doi.org/10.1016/j.cell.2023.09.013 Cell VOLUME 186, ISSUE 22, P4851-4867.E20, OCTOBER, 2023 Highlights Summary Post-acute sequelae of COVID-19 (PASC, “Long COVID”) pose a significant global health challenge. The pathophysiology is unknown, and no effective treatments have been found to date. Several […]